2248. Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort

BACKGROUND: Tenofovir alafenamide (TAF) was approved in 2015 for use in HIV-1. TAF decreases risk of renal and bone toxicity compared with tenofovir disproxil fumarate (TDF). Early clinical trials reported median increases in low-density lipoprotein (LDL) of 20–29 and 9–13 mg/dL for total cholestero...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Ewers, Evan, Won, Seunghyun, Okulicz, Jason, Ferguson, Tomas, Deiss, Robert, Maves, Ryan, Kronmann, Karl, Lalani, Tahaniyat, Agan, Brian, Whitman, Timothy J, Ganesan, Anuradha
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252728/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1901
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares